Black Diamond Therapeutics, Inc. (BDTX) vs Polaryx Therapeutics, Inc. Common Stock (PLYX)

A side-by-side comparison of Black Diamond Therapeutics, Inc. and Polaryx Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BDTX vs PLYX

growth of $100 · dividends reinvested · last 1y
BDTX -22.1% (-22.1%/yr)PLYX -94.1% (-94.1%/yr)BDTX compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100$78$6
BDTX PLYX

BDTX vs PLYX: by the numbers

  • •BDTX is the larger company ($109M vs $106M market cap).
  • •BDTX is profitable (31.95% net margin) while PLYX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricBDTXPLYX
P/B ratio1.139.66

Profitability

MetricBDTXPLYX
Gross margin99.54%0.00%
Operating margin28.39%0.00%
Net margin31.95%0.00%
ROE-44.29%-62.61%
ROIC-47.54%-47.75%

Growth (annualized)

MetricBDTXPLYX
Total return CAGR (5Y)-24.47%N/A

Frequently asked

Is BDTX or PLYX more profitable?
BDTX runs the higher net margin — BDTX at 31.95% versus PLYX at 0.00%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.